Ogkologos

4396 ΔΗΜΟΣΙΕΥΣΕΙΣ 0 ΣΧΟΛΙΑ

FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection

Ogkologos - 2 Οκτωβρίου, 2025

Study presents an AI-guided approach to target cancer antigens

Ogkologos - 1 Οκτωβρίου, 2025

Efficacy of ICI Combined with Chemotherapy in Patients with Advanced Penile...

Ogkologos - 1 Οκτωβρίου, 2025

Low-Dose Adjuvant Aspirin Decreases Incidence of Recurrence Among Patients with Resected...

Ogkologos - 30 Σεπτεμβρίου, 2025

HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy...

Ogkologos - 29 Σεπτεμβρίου, 2025

EMA Recommends Granting a Marketing Authorisation for Elinzanetant

Ogkologos - 26 Σεπτεμβρίου, 2025

ESMO Calls on EU Research Ministers to Prioritise Cancer Research Funding...

Ogkologos - 25 Σεπτεμβρίου, 2025

AI is impacting cancer care, but also the environment

Ogkologos - 25 Σεπτεμβρίου, 2025

FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and...

Ogkologos - 25 Σεπτεμβρίου, 2025

Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant,...

Ogkologos - 24 Σεπτεμβρίου, 2025

1...373839...440 Σελίδα 38 από 440

MOST POPULAR

Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed...

6 Αυγούστου, 2025

GD2-CART01 May Induce Sustained Antitumour Effect in a Proportion of Patients...

13 Απριλίου, 2023

Genomic Alterations Enriched in Young Women with HR-positive, HER2-negative Early Breast...

9 Φεβρουαρίου, 2023

Study Shows Supplements Increase Risk of Relapse and Death in Breast...

7 Ιανουαρίου, 2020

Φόρτωση περισσοτέρων

FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection

Study presents an AI-guided approach to target cancer antigens

Efficacy of ICI Combined with Chemotherapy in Patients with Advanced Penile...

Low-Dose Adjuvant Aspirin Decreases Incidence of Recurrence Among Patients with Resected...

HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy...

EMA Recommends Granting a Marketing Authorisation for Elinzanetant

ESMO Calls on EU Research Ministers to Prioritise Cancer Research Funding...

AI is impacting cancer care, but also the environment

FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and...

Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant,...

MOST POPULAR

Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed...

GD2-CART01 May Induce Sustained Antitumour Effect in a Proportion of Patients...

Genomic Alterations Enriched in Young Women with HR-positive, HER2-negative Early Breast...

Study Shows Supplements Increase Risk of Relapse and Death in Breast...

HOT NEWS

Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with...

What to Know About Navigating Cancer Care With a Disability: An...

ctDNA-Guided Treatment Influence on Survival in Advanced NSCLC

Withdrawal of the Application to Change the EMA Marketing Authorisation for...

ΔΗΜΟΦΙΛΕΊΣ ΘΈΣΕΙΣ

ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ)

ΣΤΑΤΙΣΤΙΚΑ

ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ

ΔΗΜΟΦΙΛΗ ΚΑΤΗΓΟΡΙΑ